Previous 10 | Next 10 |
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
The following slide deck was published by Trillium Therapeutics Inc. in conjunction with this Read more ...
Sonoma Pharmaceuticals (NASDAQ: SNOA ) +162% on COVID-19 nod in Australia for disinfectant. More news on: Sonoma Pharmaceuticals, Inc., Phio Pharmaceuticals Corp., Adaptimmune Therapeutics plc, Stocks on the move, , Read more ...
Dosing has progressed through first five cohorts up to 4 mg/kg dose level Strong safety profile, with no dose-limiting toxicities observed Monotherapy activity (1 CR and 1 PR) observed in DLBCL patients Further dose escalation is underway, currently dosing at 8 mg/kg ...
Trillium Therapeutics (NASDAQ: TRIL ): Q1 GAAP EPS of -$1.07 misses by $0.97 . More news on: Trillium Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and op...
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel ...
The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. From exciting new technology to the FDA’s ‘fast-trac...
CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has est...
The stock crash of 2020 has produced a lot of losers. But it’s also forged some winners. One of the industries that is most likely to benefit from the COVID-19 outbreak and profit in the long-term is biotech. Sure, they’re not always the most stable investments. Firms t...
News, Short Squeeze, Breakout and More Instantly...
Trillium Therapeutics Inc. Company Name:
TRIL Stock Symbol:
NASDAQ Market:
Trillium Therapeutics Inc. Website:
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributors Keith Speights and Brian Orelli explain why the news of a discontinued drug from the pharmaceutical giant hasn't shaken investors. Keith Speights: Pf...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce...